REG - OptiBiotix Health - Appointment of Commercial Director <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

05/01/2017 07:06

RNS Number : 3790T
OptiBiotix Health PLC
05 January 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of New Commercial Director
OptiBiotixHealthplc(AIM: OPTI),alifesciencesbusinessdevelopingcompoundstotackleobesity,high cholesterol,diabetes and skin care, announces the departure of Jim Laird by mutual agreement and the appointment of Per Rehn as Commercial Director. Per will join the OptiBiotix Board subject to completion of the normal regulatory due diligence. 
Per has many years experience of the food industry, having worked for some of the world's leading food companies including Danisco (acquired by Dupont in 2011 for US$6.3bn), and specialised food ingredient suppliers including roles as Managing Director of both Frutarom Nordic A/S (A subsidiary of Frutarom Industries Ltd) and Innotaste Nordic A/S. More recently, Per has worked as European Director of Health and Nutrition at Cornelius Group plc which under his leadership became the company's fastest growing business unit, quadrupling sales from a low base to double digit million pound revenues in less than three years.
Per has extensive experience in building business-to-business sales through commercial partnerships and working with manufacturers and distributors to rapidly grow sales revenues in international markets. A proven Commercial Director, Per comes with a wide network of contacts in the food industry and a track record of closing out commercial deals. 
Per is a qualified food technologist and is multilingual in English, Danish, German, Swedish and Norwegian. His experience of food, health, and nutrition markets will help drive commercialisation of OptiBiotix's growing pipeline of products and create multiple revenue streams across all technology platforms.
Stephen O'Hara, CEO of OptiBiotix, commented: "Per's experience and track record of growing business-to-business sales of ingredients and nutritional productsbrings operational commercial and industry expertise to OptiBiotix.His network of contacts provides access to new international markets to help drive revenue growth from OptiBiotix's growing pipeline of products now entering their commercialisation phase. These include OptiBiotix's patented SlimBiome technology for hunger free weight loss and its LP-LDL probiotic strain for cholesterol and hypertension reduction. This is consistent with the overall aim of developing multiple revenue streams from both consumer and pharmaceutical products across all OptiBiotix's technology platforms. On behalf of the Board, I would like to thank Jim for his hard work and dedication to the Company and we wish him well in his future projects."
For further information, please contact:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP
Tel: 020 7213 0883
Liam Murray

finnCap Broker
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCUSVBRBKAARAR